Institutional members access full text with Ovid®

Share this article on:

Transplantation of Human Marrow Stromal Cells and Mono-Nuclear Bone Marrow Cells Into the Injured Spinal Cord: A Comparative Study

Samdani, Amer F. MD*; Paul, Courtney BS; Betz, Randal R. MD*; Fischer, Itzhak PhD; Neuhuber, Birgit PhD

doi: 10.1097/BRS.0b013e3181bdca87
Basic Science

Study Design. Two groups of 6 rats received dorsolateral funiculotomies followed by direct injection of bone marrow stromal cells (MSC) or mono-nuclear fraction of bone marrow (mnBM). Animals were killed at 4 or 21 days.

Objective. Cellular transplantation is a promising treatment strategy for spinal cord injury (SCI); however, most cells need to be cultured before transplantation introducing burdensome steps for clinical application. Cells immediately available for transplantation, like mnBM, would be preferable.

Summary of Background Data. Previous studies have shown that MSC transplants promote protection and repair after SCI. MSC are attractive for transplantation because of easy isolation and availability of autologous sources. MSC are derived from whole bone marrow, purified and expanded in culture for a period of at least 2 weeks. Alternatively, mnBM could be used for transplantation. mnBM derived from bone marrow from through simple centrifugation can be reimplantated within hours; however, the presence of immune cells may be problematic.

Methods. Cultured MSC or mnBM from human donors were acutely transplanted into SCI. After sacrifice, spinal cord sections were histologically analyzed for presence of graft-derived immune cells, host immune response, tissue sparing, glial scar formation, and grafting efficacy.

Results. mnBM did not give rise to mature immune cells after transplantation into SCI, or evoke an increased host immune response or tissue loss compared to MSC-transplanted animals. In contrast, host macrophage/microglia response was increased early after MSC transplantation, perhaps due to exposure of cells to serum-containing media. The glial scar was less prominent after mnBM transplantation at day 4. At 21 days, differences had subsided and MSC and mnBM macrophage responses and effects on glial scarring were comparable. MSC and mnBM engraftment efficiencies were also similar.

Conclusion. The use of mnBM is a viable alternative to MSC for transplantation into SCI and may dramatically ease clinical translation.

Bone marrow stromal cells or cells comprising the mono-nuclear fraction of bone marrow were transplanted into spinal cord injury. Histologic evaluation of transplant efficacy established that mnBM is a practical alternative to marrow stromal cells for transplantation into spinal cord injury that does not require cell culture.

From the *Shriners Hospital for Children, Philadelphia, PA; and †Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA.

Acknowledgment date: February 24, 2009. Revision date: April 2, 2009. Acceptance date: April 6, 2009.

The manuscript submitted does not contain information about medical device(s)/drug(s).

Foundation funds were received in support of this work. No benefits in any form have been or will be received from a commercial party related directly or indirectly to the subject of this manuscript.

A.F.S. and C.P. contributed equally to the manuscript.

Supported by Shriners Hospital for Children grants # 8251 (to I.F.) and 8570 (to A.F.S.).

Address correspondence and reprint requests to Amer F. Samdani, MD, Shriners Hospital for Children, 3551 N, Broad St, Philadelphia, PA 19140; E-mail:

© 2009 Lippincott Williams & Wilkins, Inc.